RxDoctor Payments Data

Hongwu Wang, MD

Internal Medicine · Houston, TXNPI 1396908992

Payments from drug & device makers

$495in general payments, 2019–2025

Across 24 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$113
  • Dexcom, Inc.$54
  • Amgen$47
  • Biosense Webster, Inc.$38
  • Novo Nordisk$36
  • Johnson & Johnson$35
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$495 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,819
Medicare patients
308
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$138,684
JardianceEmpagliflozin23$33,110
FarxigaDapagliflozin Propanediol20$31,121
MounjaroTirzepatide20$24,299
ProliaDenosumab14$24,114
TrulicityDulaglutide12$23,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,842
Atorvastatin Calcium623$7,340
Rosuvastatin Calcium250$5,881
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,238
Levothyroxine Sodium385$4,106
Amlodipine Besylate507$3,110
Losartan Potassium263$2,729
SynthroidLevothyroxine Sodium39$2,488
Nifedipine ErNifedipine77$2,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$138,684106 claims
Lilly USA, LLCMounjaro, Trulicity$15$47,59932 claims
AstraZenecaFarxiga$29$31,12120 claims
AmgenProlia$47$24,11414 claims
GSKTrelegy Ellipta$19$13,84212 claims
ANI Pharmaceuticals, Inc.Valsartan$30$1,13841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →